Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session
Cardio Diagnostics' mission is to redefine cardiovascular care by combining epigenetics, genetics, and artificial intelligence to enable earlier detection of heart disease and more personalized patient management. Through our commitment to data-driven innovation, Cardio Diagnostics aims to prevent heart disease, improve diagnostic accuracy, and enable clinicians with actionable insights to deliver targeted, effective care.
Spotlight on PrecisionCHD™ and Actionable Clinical Intelligence (ACI™)
PrecisionCHD™, Cardio Diagnostics' flagship solution, is a clinical blood test available by prescription to aid in the diagnosis and management of coronary heart disease (CHD). Unlike traditional diagnostic tools, PrecisionCHD™ is radiation-free, requires no fasting, and is performed through a simple blood draw, either via standard phlebotomy or lancet-based sampling. By evaluating a unique panel of 10 genetic and 6 epigenetic (DNA methylation) markers, PrecisionCHD™ provides clinicians with deep insights into the unique underlying molecular drivers of CHD for each patient.
Importantly, the test results map epigenetic biomarkers to modifiable risk factors, allowing clinicians to personalize patient management. For cardiologists, PrecisionCHD™ serves as a critical tool in the fight against CHD, offering a non-invasive, radiation-free method to assess molecular drivers of CHD that traditional diagnostics may overlook. With the ability to track changes over time, PrecisionCHD™ empowers cardiologists to refine treatment plans based on a patient's unique epigenetic profile, ultimately driving more effective interventions and better long-term cardiovascular outcomes.
This year at ACC.25, Cardio Diagnostics will specifically highlight the updated Actionable Clinical Intelligence (ACI™) report for PrecisionCHD™, now enhanced to provide clearer, easier-to-interpret and more actionable clinical insights. The updated ACI™ leverages PrecisionCHD™'s six key methylation markers, giving prescribing clinicians sharper visibility into their patients' modifiable drivers of disease, including inflammation-related risk - a critical advancement for personalized care.
'PrecisionCHD™ and our enhanced Actionable Clinical Intelligence™ deliver a level of insight that no other solution offers cardiologists today,' said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. 'By integrating epigenetics, genetics, and AI, we provide a clearer, more actionable understanding of a patient's modifiable drivers of coronary heart disease. This empowers cardiologists to deliver truly personalized care and improve patient outcomes.'
Poster Presentation - Methylation Biomarkers as Predictors of Mortality in ACS Patients: A Critical Advancement for Clinical Cardiology
At ACC.25, Cardio Diagnostics will present compelling new data on the power of the methylation biomarkers of the PrecisionCHD™ test to predict mortality in patients with Acute Coronary Syndrome (ACS), offering cardiologists a novel, actionable tool to guide patient management to help improve survival outcomes.
The poster, titled 'Synergistic Effects of Combining Methylation Data with Imaging Data in Predicting Mortality of Acute Coronary Syndrome (ACS) Patients,' highlights findings from a recent study by Cardio Diagnostics demonstrating the superiority of PrecisionCHD methylation indices to angiographic methods for predicting mortality risk in ACS patients. In addition, the study delineates a machine learning-based method that could be integrated within existing electronic health records systems to synergistically combine angiographic and methylation information for predicting mortality risk.
By interrogating key methylation pathways linked to inflammation and coronary heart disease, PrecisionCHD™ can enable clinicians to more effectively stratify mortality risk and personalize treatment plans for ACS patients, potentially improving outcomes.
'These findings underscore the power of methylation-based biomarkers in cardiovascular medicine,' said Rob Philibert, M.D., Ph.D., Chief Medical Officer of Cardio Diagnostics. 'Traditional imaging tools provide valuable anatomical insights, but they fall short in predicting long-term mortality risk and providing mechanistic insights. Our study shows that methylation biomarkers not only fill this gap but also offer a more precise, biologically driven assessment of mortality risk, allowing cardiologists to intervene earlier and more effectively.'
Visit Cardio Diagnostics at Booth #2033
Attendees are invited to visit Booth #2033 to learn more about the Company's PrecisionCHD™, Epi+Gen CHD™ and Actionable Clinical Intelligence™ solutions, and its broader vision for AI-driven, epigenetic-guided precision cardiovascular medicine. The Company's executive team will also be onsite to engage with cardiologists, potential partners and attendees on how these innovations are transforming cardiovascular care.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ('Core Technology') for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/
Forward-Looking Statements
Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, under the heading 'Risk Factors' in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
Investor Relations
855-226-9991
[email protected] & Public Relations
Public Relations
855-226-9991
SOURCE: Cardio Diagnostics Holdings, Inc.
Copyright Business Wire 2025.
PUB: 03/26/2025 08:31 AM/DISC: 03/26/2025 08:32 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
3 hours ago
- Miami Herald
GameSquare Regains Compliance with Nasdaq's Minimum Bid Price Requirement
FRISCO, TX / ACCESS Newswire / July 25, 2025 / GameSquare Holdings, Inc. (NASDAQ:GAME) today announced that it received formal written confirmation from The Nasdaq Stock Market, LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq's minimum bid price requirement. To regain compliance with the Minimum Bid Price Requirement, the Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The closing bid price of the shares has been at $1.00 per share or greater for 10 consecutive business days from July 8 to July 21, 2025. Accordingly, Nasdaq Listing Qualifications Staff has notified the Company that it has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed. About GameSquare Holdings, Inc. GameSquare (NASDAQ: GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. Complementing our operating strategy, GameSquare operates a blockchain-native Ethereum treasury management program designed to generate onchain yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation. To learn more, visit Forward-Looking Statements: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company's future performance, revenue, growth and profitability; and the Company's ability to execute on its current and future business plans. These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company's ability to grow its business and being able to execute on its business plans, the success of Company's vendors and partners in their provision of services to the Company, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company's ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company's portfolio across entertainment and media platforms, dependence on the Company's key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company's most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. GameSquare Corporate Contact Lou Schwartz, PresidentPhone: (216) 464-6400Email: ir@ GameSquare Investor Relations Andrew BergerPhone: (216) 464-6400Email: ir@ GameSquare Media Relations Chelsey Northern / The UntoldPhone: (254) 855-4028Email: pr@ SOURCE: GameSquare Holdings, Inc.
Miami Herald
3 hours ago
- Miami Herald
32.5 Million Engines Later, Honda's Ohio Plant Turns 40
Honda is celebrating 40 years of engine production at its Anna Engine Plant in Ohio. What started as a modest motorcycle engine facility in the mid-80s has grown into the company's largest engine plant in the world. As Honda shifts toward hybrid and electric power, shown by models like the new hybrid Prelude, the Anna plant is evolving to keep pace with the future of mobility. Since opening its doors in 1985, the Anna Engine Plant has built over 32.5 million engines. That includes everything from basic four-cylinders for the Civic to high-output V6s found in Acura performance cars and SUVs. Back then, it was a 200,000 square-foot facility with fewer than 100 workers. Today, it covers 2.8 million square feet and supports nearly 3,000 employees. The plant currently produces a wide range of four-cylinder and V6 engines, including turbocharged and hybrid variants. It also makes essential components like cylinder heads, camshafts, crankshafts, and the precision pulleys used in Honda's CVTs. Engines from Anna have powered some of Honda's most iconic vehicles. The plant builds the 190-hp 1.5-liter turbo used in the Civic, Accord, CR-V, and Acura Integra, as well as the 315-hp 2.0-liter turbo found in the Civic Type R and Integra Type S. It even produced the 500-hp 3.5-liter twin-turbo V6 that lived in the second-generation Acura NSX supercar. But Anna's output isn't all about performance. It's also behind the hybrid engines that help fuel-efficient models like the Accord and CR-V deliver impressive fuel economy. It's clear as day that the Anna Engine Plant has played a huge role in shaping Honda and Acura's lineup across North America. While gas and hybrid engines are still a major focus, Anna is already preparing for Honda's next chapter. The plant has started producing aluminum battery cases for upcoming EVs, using cutting-edge processes like megacasting, Minimum Quantity Lubrication machining, and friction stir welding. These battery cases will be shipped to the Marysville Auto Plant, where they'll be paired with battery modules to power the next generation of Honda and Acura electric vehicles, including the Honda Prologue. Full EV production is set to begin in Ohio in 2026. With four decades of experience and a clear role in Honda's future, the Anna Engine Plant continues to be a key part of the company's evolution. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Yahoo
21 hours ago
- Yahoo
Yext, Inc. (YEXT) Launches New Search Initiative, Yext Research
With a share price under $10, strong hedge fund interest, and a low price-to-earnings ratio, Yext, Inc. (NYSE:YEXT) makes it onto our list of the . A data centre room with cloud technology, illustrating the enterprise application software services. On June 13, 2025, Yext, Inc. (NYSE:YEXT) announced the launch of Yext Research, which is a new initiative that provides deeper insights to marketers and SEO professionals into how brands are discovered in today's complex search landscape. Leveraging over 2 billion data points, the new search initiative fills the gap in industry benchmarks and performance signals. Furthermore, the program also introduces Yext Research Partners, a collaborative model that invites experts to publish independent, data-driven insights. This comes ahead of Yext, Inc. (NYSE:YEXT)'s solid performance for Q1 FY25, which ended on April 30, 2025. The earnings result, which was released on June 3, 2025, was marked by a 14% YoY increase in revenue that reached $109.5 million. Strong demand across the company's platform contributed to the sales growth. Meanwhile, a record $24.7 million adjusted EBITDA was achieved, reflecting a 23% margin. A favorable currency impact and the acquisition of Hearsay Systems contributed to the company's performance, boosting its Annual Recurring Revenue (ARR) by 15% YoY. Yext, Inc. (NYSE:YEXT) keeps an optimistic future outlook with plans to scale up its innovative product, Yext Scout. The product, in beta, is gaining significant traction, boasting over 1,000 sign-ups and a strong response from enterprise customers. With the Yext platform, a cloud-based solution, Yext, Inc. (NYSE:YEXT) specializes in digital knowledge management and search solutions. It is included in our list of the best cloud stocks. While we acknowledge the potential of YEXT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and Top 10 AI Infrastructure Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
